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The activation of signal transducer and activator of transcription 3 (Stat3) has been implicated in the oncogenesis of cancer and is
regarded as a novel target for cancer therapy. Stat3 is classified as a proto-oncogene, because an activated form of Stat3 can mediate
oncogenic transformation in cultured cells and tumour formation in nude mice. The constitutive activation of Stat3 has been
frequently detected in various types of human cancers. However, the constitutive activation of Stat3 in endometrial and cervical
cancers has not been studied. We examined tyrosine phosphorylation of Stat3 (activated form of Stat3) in multiple endometrial and
cervical cancer tissues using tissue microarray slides as well as cancer cell lines to explore the possible activation of Stat3. Our results
indicated that elevated phosphorylation of Stat3 was detected in cervical and endometrial cancer cell lines. Our results also showed
that elevated levels of phosphorylation of Stat3 protein were detected in the endometrial and cervical cancer specimens. This is the
first study to demonstrate that Stat3 is activated in human endometrial and cervical cancer tissues. Immunohistochemical staining
showed that activated Stat3 is associated with increased expression of downstream antiapoptotic genes, Bcl-xL, survivin, and Mcl-1 in
these tissues. Expression of a dominant-negative Stat3 mutant using adenovirus-mediated gene transfer inhibited cell growth and
induced apoptosis in HeLa and SiHa cervical cancer cell lines expressing elevated levels of Stat3 phosphorylation. Further, a JAK/Stat3
small molecular inhibitor, JSI-124, induced apoptosis more selectively in HeLa and SiHa cancer cell lines than Ishikawa cell line without
elevated levels of Stat3 phosphorylation. These results indicate that Stat3 is activated in human endometrial and cervical cancers and
the inhibition of constitutive Stat3 signaling may be an effective target for cancer intervention in these two cancers.
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Signal transducer and activator of transcription signaling pathways
are activated in response to cytokines and growth factors (Darnell
et al, 1994; Zhong et al, 1994). JAKs, Src, and epidermal growth
factor receptor (EGFR) are some of the potential upstream
activators of Stat3 (Sartor et al, 1997; Bromberg et al, 1998; Garcia
et al, 2001). Stat3 is activated by phosphorylation at tyrosine (Tyr)
residue 705, which leads to dimer formation, nuclear translocation,
recognition of Stat3-specific DNA-binding elements, and activa-
tion of target gene transcription (Darnell et al, 1994; Zhong et al,
1994). A growing number of human malignancies and tumour
formation are associated with high levels of activation of signal
transducers and activators of transcription (STATs), very fre-
quently Stat3 and Stat5 (Garcia et al, 1997; Garcia and Jove, 1998;
Bowman et al, 2000). Stat3, as a major member of the STAT family
consisting of Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b, and Stat6,
plays important roles in cell differentiation and proliferation
(Darnell et al, 1994; Schaefer et al, 1995; Buettner et al, 2002). Stat3
appears to be involved in the regulation of multiple systematic
signal pathways and acts as a multi-functional protein. For
example, Stat3 deletion in mice leads to embryonic lethality (Shen
et al, 2004). It has been reported that Stat3 activation is sufficient
to maintain an undifferentiated state of mouse embryonic stem
cells (Niwa et al, 1998; Matsuda et al, 1999; Raz et al, 1999). In
breast and hematopoietic cells, existing evidence demonstrate that
Stat3 acts as an oncogenic protein and may be associated with
chemotherapeutic resistance (Dalton and Jove, 1999; Rebbaa et al,
2001; Pollett et al, 2002; Real et al, 2002).
In a variety of human cancers, constitutive activation of Stat3
is sufficient to induce tumour formation (Bromberg et al, 1999;
Buettner et al, 2002). The constitutive activation of Stat3 is
frequently detected in a variety of human cancers (Bowman et al,
2000; Huang et al, 2000). Stat3 has been classified as a proto-
oncogene because an activated form of Stat3 can mediate
oncogenic transformation in cultured cells and tumour formation
in nude mice (Bromberg et al, 1999; Bowman et al, 2000).
Constitutive Stat3 signaling may participate in oncogenesis by
stimulating cell proliferation, promoting angiogenesis, mediating
immune evasion, and conferring resistance to apoptosis induced
by conventional therapies (Niu et al, 2002; Real et al, 2002; Wei
et al, 2003; Wang et al, 2004). Inhibition of constitutively active
Stat3 can induce apoptosis and inhibit cancer cell growth (Buettner
et al, 2002), indicating constitutive Stat3 signaling is required for
cancer cell survival and growth. Although the constitutive
activation of Stat3 has been detected in various types of human
cancers, there is no report on whether Stat3 is activated in
endometrial cancer and cervical cancer tissues. Given that Stat3
can contribute to cancer progression and tumour angiogenesis, it Revised 14 December 2006; accepted 19 December 2006
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sis important to explore whether Stat3 is also activated in
endometrial and cervical cancers. Therefore, we examined the
Tyr phosphorylation of Stat3 at residue 705 (activated form of
Stat3) in human endometrial and cervical cancer tissue microarray
slides that contain multiple cancer specimens. Our results
indicated that elevated levels of phosphorylation of Stat3 protein
at Tyr residue 705 and serine residue 727 (Ser727) were detected in
endometrial and cervical cancer specimens. These results suggest
that activated Stat3 signaling may contribute to carcinogenesis in
human endometrial and cervical carcinomas. We also showed that
expression of a dominant-negative Stat3 mutant and a JAK/Stat3
small molecular inhibitor, JSI-124, induced apoptosis in HeLa and
SiHa human cervical cancer cell lines expressing elevated levels of
phosphorylated Stat3.
MATERIALS AND METHODS
Tissue microarray slides and immunohistochemistry
Human endometrial and cervical cancer tissue microarray slides
were obtained from US Biomax Inc. (Ijamsville, MD, USA), Cybrdi
Company (Frederick, MD, USA), and Imgenex Corporation (San
Diego, CA, USA). These slides were baked at 60–651C at various
time periods according to the manufacturer’s instruction, depar-
affinised in xylene three times, transferred through two changes of
100% and 95% ethanol, and then rehydrated with graded ethanol.
Antigen retrieval was done by boiling the slides in a small beaker
filled with 10mM Sodium Citrate (pH 6.0) or 1mM EDTA (pH 8.0).
Endogenous peroxidase activity was quenched by a 10-min
incubation in 3% hydrogen peroxide. After antigen retrieval,
the slides were washed two times in a 0.1% Tween/1  TBS
(0.1% TBST) bath (5min each) at room temperature to remove
nonspecific background binding. Protein blocking was performed
by incubating the specimens in 5% normal goat serum or normal
horse serum in 0.1% TBS for 1h. The primary antibody was
applied for 1h at room temperature (1:30 dilution of anti-p-Stat3
(Y705) and (S727) antibody (Cell Signaling Technology, Beverly,
MA, USA) and anti-Bcl-xL, -survivin (BD Sciences, Franklin Lakes,
NJ, USA), and -Mcl-1 antibodies (Lab Vision, Corp. Fremont, CA,
USA), in 0.1% TBST with normal serum or 1:50–100 dilution of
antibodies that recognise Stat3 downstream targets in 0.1% TBST
with normal serum. After a series of TBST rinses as described
above, bound antibody was subsequently detected using a
VETASTATIN ABC kit from VECTOR Laboratories, Inc. (Burlingame,
CA, USA). For visualisations, the sections were then incubated with
3-amino-9-ethylcarbazole (AEC) high-sensitivity substrate chromogen
from DakoCytomation (Carpinteria, CA, USA) for 2–30min. Finally,
the slides were counterstained with hematoxylin and mounted with
CRYSTAL/MOUNT (Biomeda Corp., Foster City, CA, USA) for long-
term preservation.
Evaluation of immunohistochemical staining and
statistical analysis
Immunostained slides were scored under microscope. The staining
intensity was scored on the following scale: 0, no staining; 1, weak
staining; 2, moderate staining; and 3, intense staining. Most or all
of the cancer tissues showed staining in greater than 50% of the
area. Scoring of the tissue microarray was completed by three
independent researchers (JB, CC, and JL). Discrepant scores
between three observers or researchers were re-scored to arrive at
a single final score. As most of the normal tissues stained were
scored as 0 but a few samples scored as 1, we therefore considered
cancer samples with scores 2 and 3 were positive staining. The
association of p-Stat3 (Tyr705) with the expression p-Stat3
(Ser727) and potential downstream genes was analysed using
Pearson w
2 test.
Cell lines and culture
Human endometrial cancer cell lines, RL95-2, Hec-1B and cervical
cancer cell lines, C33A, HeLa, SiHa, and HT-3, and human
papillomavirus E6/E7 (Ect1/E6E7)-immortalised cervical cell line
were purchased from the American Type Culture Collection
(ATCC). Ishikawa endometrial cancer cell line was kindly provided
by Dr M Nishida. Hec-1B, C33A, HeLa, and SiHa were cultured
in DMEM medium containing 10% fetal bovine serum (FBS), 100
U/ml penicillin and 100mg/ml streptomycin (Invitrogen Life
Technologies, Carlsbad, CA, USA). Ect1/E6E7-immortalised cervi-
cal cell line was cultured in keratinocyte-serum free medium
containing 10% FBS, 100U/ml penicillin and 100mg/ml strepto-
mycin, 0.1ng/ml EGF and 0.05mg/ml bovine pituitary extract
(Invitrogen Life Technologies, Carlsbad, CA, USA). RL95-2
cells were cultured in medium containing 10% FBS, 100U/ml
penicillin and 100mg/ml streptomycin, and supplemented with
0.005mg/ml insulin (Invitrogen Life Technologies, Carlsbad, CA,
USA). HT-3 cells were cultured in McCoy’s 5a medium containing
10% FBS, 100U/ml penicillin and 100mg/ml streptomycin
(Biosource, Rockville, MD, USA). Cells were grown as attached
monolayers and incubated in a humidified atmosphere with 5%
CO2 at 371C.
Western blot
Cells were collected at 41C in cold harvest buffer, supplemented
with proteinase inhibitor cocktails and spun down at 3000g for
5min. Cell pellets were lysed in RIPA lysis buffer as described
previously (Hsieh et al, 2005). Protein concentrations were
quantitated using BCA protein assay kit from Pierce, Inc.
(Rockford, IL, USA) according to the manufacture’s protocol.
Fifty or 100mg of cellular proteins were resolved on 10% PAGE gels
in electrophoresis buffer and transferred to Hybondt-p membrane
(Amersham Biosciences, Piscataway, NJ, USA) using transfer
buffer with constant 100V. The membranes were then blocked
using 5% nonfat dry milk in TBST (Tris-HCl, pH 7.5, Tween, 0.1%)
for 30min at room temperature (RT) and were incubated with
primary antibody over night at 41C or for 1h at RT using
concentrations recommended by the manufacturer. The mem-
branes were washed three times in 1 TBST for 5min each time.
Proteins of interest were visualised using ECFt Western blotting
kit (Amersham Biosciences, Piscataway, NJ, USA) according to the
manufacturer’s protocol. Incubation of secondary antibody and
anti-fluorescein was carried out both in presence of 1  TBST with
2% nonfat dry milk. The fluorescent signals were scanned and
documented using a Storm 860 scanner (Molecular Dynamics,
Sunnyvale, CA, USA).
Antibodies against phospho-specific Stat3 (p-Stat3) (Tyr705 and
Ser727), total Stat3, phospho-specific Stat1 (p-Stat1) (Tyr701),
phospho-specific Stat5 (p-Stat5) (Tyr694) (Cell Signaling Techno-
logy, Beverly, MA, USA) were used to detect corresponding
proteins on the membrane, respectively. A monoclonal antibody
against glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Chemicon International, Temecula, CA, USA) and a monoclonal
antibody recognising FLAG (Sigma, St. Louis, MO, USA) were used
to detect GAPDH as an internal protein loading control in all
Western blots and to detect FLAG-tagged Stat3, respectively. To
detect apoptosis, HeLa and SiHa cancer cells were transduced by
either rAd/eGFP or rAd/dnStat3 for 2 days and then cell lysates
were subjected to Western blotting using a monoclonal antibody
that specifically recognises cleaved PARP (Asp214) (Cell Singling
Tech. Danvers, MA, USA). The quantification of p-Stat3 (Tyr705)
and p-Stat3 (Ser727) expressions was carried out using ImageQuan
software (Molecular Dynamics, Sunnyvale, CA, USA). The
expressions were normalised to GAPDH and shown as the
percentages of p-Stat3 (Tyr705) in SiHa cells and p-Stat3
(Ser727) in RL95-2 cells.
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cells
The construction of recombinant adenovirus/CMVdnStat3 Y705F
(rAd/dnStat3) is described previously (Kunisada et al, 1998).
DnStat3 was generated from Stat3 by changing the Tyr at position
705 into phenylalanine. Its protein product cannot be activated
through Tyr phosphorylation. The clone is tagged with a FLAG
marker. About 2 10
5HeLa and SiHa cells were transduced with
rAd/dNStat3 (Y705F) or rAd/eGFP (negative control viral vector)
with multiplicities of infection (MOI) 400, 100, and 10. The cells
were observed for cell growth and apoptosis at day 2 post-
infection. Cell numbers of three random fields of views
(magnification  100) were scored for each rAd/dnStat3-trans-
duced cells and negative controls in three independent experi-
ments. For cell viability assay, about 1 10
4HeLa, SiHa, and
Ishikawa cells were seeded in triplicates in 96-well plates with
100ml medium overnight and transduced with rAd/dnStat3
(Y705F) or rAd/eGFP (MOI¼250). Cells were subjected to 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) (Sigma-Aldrich, USA) cell viability assay 2 days later
(Denizot and Lang, 1986). Cells were incubated with MTT
(40mgml
 1) for 4h and lysed in 20% SDS and 50% N,N-
dimethylformamide (pH 4.5) and spectrophotometric reading
was performed at OD595 by an EL808 Ultra Microplate Reader
(Bio-Tek Instruments, Inc, Winooski, VT, USA).
Cleaved caspase 3 immunofluorescent staining
About 1 10
5 cells (HeLa and SiHa) were seeded on sterile
coverslips in a six-well plate overnight. The cells were transduced
by either rAd/eGFP or rAd/dnStat3 for 2 days and then fixed using
methanol/acetone (v:v¼1:1). The cells incubated with 5 and 10mM
JSI-124 (cucurbitacin I) (EMD Biosciences, Inc. La Jolla, CA, USA),
a JAK/Stat3 inhibitor, and DMSO (1:1000 dilution) served as
positive and negative controls, respectively (Blaskovich et al,
2003). The cells were fixed using methanol/acetone after 24h.
Three washes followed the fixation using 1  PBS buffer. During
the third wash, the coverslips were transferred to a new six-well
plate. For immunofluorescent staining, the cells were blocked in
1  PBS with 10% normal horse serum for 1h and incubated with
primary rabbit antibodies that recognise cleaved-caspase-3
(Asp175) (Cell Singling Tech., Danvers, MA, USA) with 1:100,
1:50, and 1:100 dilution, respectively. Excess antibodies were
removed using three washes of 1  PBS with constant agitation,
10min for each wash. Secondary goat anti-rabbit IgG(HþL) Alexa
Fluor 594 antibody (Invitrogen, Carlsbad, CA, USA) (1:1000
dilution) was incubated with 1% bovine serum albumin in 1 
PBS for 1h at RT. Unbound antibody was washed off three times
using 1  PBS. Nuclei were counterstained using 40-6-diamidino-
2-phenylindole (DAPI) (100ng/ml) in distiled H2O for 5min, and
then rinsed three times with 1  PBS, 10min for each wash. The
fluorescence and phase-contrast microscopic photographs were
documented using LEICA DM-IRB inverted fluorescent micro-
scope (Leica Microsystems, Inc., Bannockburn, IL, USA) with an
attached Diagnostic RT-SE6 monochrome digital camera (Diag-
nostic Instruments, Inc, Sterling Heights, MI, USA).
RESULTS
Increased tyrosine phosphorylation of Stat3 in endometrial
and cervical cancer tissues
A total of 115 endometrial cancer specimens and five normal
endometrial specimens were included on the microarray slides.
Most of the endometrial cancer patients are between ages 46 and
80 and grades I and II (Supplementary Table 1). The most common
cancer type in these tissue microarray slides was endometrial
adenocarcinoma. We first examined the phosphorylation of Stat3
in endometrial cancer specimens. Our results showed that elevated
levels of the phosphorylation (Tyr705) of Stat3 protein were
detected in the nuclei of 24 out of 115 total endometrial cancer
specimens (Supplementary Table 1). The representative examples
of phosphorylated Stat3 staining in normal tissues and positive
staining of endometrial cancer tissues (grades I, II, and III) are
shown in Figure 1A. Positive p-Stat3 staining (Scores 2 and 3)
were detected in 11.8% of patients in grade I, 25.8% of patients in
AB
Normal tissue Endometrial adenocarcinoma (grade I)
Endometrial adenocarcinoma (grade II) Endometrial adenocarcinoma (grade III)
Squamous cell carcinoma (stages IA1 – IIB)
Normal cervical tissue Stage IA1 Stage IB1
Stage IB2 Stage IIA Stage IIB
Figure 1 Expression of Stat3 phosphorylation (Tyr705) in (A) endometrial cancer tissues and (B) cervical cancer tissues. Endometrial and cervical cancer
tissue microarray slides were stained using IHC methods and an IHC-validated phospho-specific Stat3 antibody (Tyr705). The representative examples of
phosphorylated Stat3 staining in normal tissues and positive staining of endometrial cancer tissues (grades I, II and III) are shown. The representative
examples of phosphorylated Stat3 staining in normal tissues and positive staining of cervical cancer tissues (different stages) are shown.
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Table 1). Normal endometrial tissues express very low levels of
phosphorylated Stat3 (Figure 1A). These results suggest that
activation of Stat3 (Tyr 705) in endometrial cancer may be as early
as at grade I but there is a slight increase in incidence at grades II
and III.
We next examined the phosphorylation of Stat3 (Tyr705) in
cervical cancer specimens. A total of 104 cervical cancer specimens
and seven normal cervical specimens were included in two
independent microarray slides. Most of the cervical cancer patients
are between ages 25 and 60 and the most common cervical cancer
type in these two tissue microarray slides was squamous cell
carcinoma. One microarray slide contains grade but no stage
information and most of the cervical cancer patients are grades II
and III (Supplementary Table 2). The other microarray slide
contains stage but no grade information (Supplementary Table 2).
Our results demonstrated that elevated levels of phosphorylation
(Tyr705) of Stat3 protein were detected in the nuclei of 25 out of
104 total cervical cancer specimens (Supplementary Table 2). The
representative examples of phosphorylated Stat3 staining in
normal tissues and positive staining of cervical cancer tissues
(different stages) are shown in Figure 1B. Positive phospho-Stat3
staining was detected in 10.8% of patients in grade II and 10.5% of
patients in grade III (Supplementary Table 2). These results
suggest that activation of Stat3 in cervical cancer can be detected at
grades II and III. We only have one specimen in grade I that is
negative, so the sample number is too small to draw conclusion for
grade I. We also observed the elevation of Stat3 phosphorylation
from Stage 0 to IIB and even detected two out of three squamous
cell carcinoma in situ (TisN0M0) are positive (Supplementary
Table 2). The elevation of Stat3 phosphorylation is also detected in
cervical cancer with or without regional lymph node metastasis
(Supplementary Table 2). These results suggest that the activation
of Stat3 can be detected throughout all different stages and the
activation of Stat3 may be a very early event in cervical cancer.
Normal cervical tissues express very low levels of phosphorylated
Stat3 (Figure 1B). We also examined the phosphorylation of Stat3
in human endometrial cancer cell lines, Ishikawa, RL-95-2, Hec-1B,
and cervical cancer cell lines, C33A, HeLa, SiHa and HT-3. Human
papillomavirus-immortalised cervical cell line (Ect1/E6E7), C33A
and all three endometrial cancer cell lines, RL-95-2, Ishikawa, and
Hec-1B express low or detectable levels of Stat3 phosphorylation.
However, elevated phosphorylation of Stat3 (Tyr705) was detected
in HeLa, SiHa, and HT-3 cervical cancer cell lines (Figure 2A and
B). This is consistent with previous results that HT-3 cervical
cancer cell line expressed elevated levels of Stat3 phosphorylation
(Page et al, 2000).
Elevated Stat3 phosphorylation at Ser residue 727 (Ser727) was
also detected in endometrial (18.3%, 11/60) and cervical (23.0%,
24/104) cancer tissues and cell lines (HT3, RL95-2 & Hec-1B)
(Figure 2A and B; Tables 1 and 2). The frequencies of elevated
p-Stat3 (Ser727) in both types of cancer tissues examined were
very similar to the frequencies of p-Stat3 (Tyr705), 20.8% and
24.0%, respectively. Concurrence of elevated p-Stat3 (Tyr705) and
p-Stat3 (Ser727) is high with 76.9% (20/26) and 63.6% (7/11) in
cervical and endometrial cancers, respectively. HT-3 cell line was
the only cell line to show high levels of expression of both p-Stat3
(Tyr705) and p-Stat3 (Ser727). HeLa and SiHa express high levels
of p-Stat3 (Tyr705) but low levels of p-Stat3 (Ser727). In contrast,
RL95-2 and Hec-1B express low levels of p-Stat3 (Tyr 705) but high
levels of p-Stat3 (Ser727).
Stat1 and Stat5 are also important STAT members related to
malignancies (Yu and Jove, 2004). The statuses of p-Stat1 (Tyr701)
and p-Stat5 (Tyr694) in the cancer cell lines were also examined
using Western blot analysis. None of eight cell lines showed signs
of elevated phosphorylation for Stat1 but slightly elevated
expression of p-Stat5 (Tyr694) was detected in C33A, HeLa and
Hec-1B cells.
Activated Stat3 is associated with increased expression of
antiapoptotic genes in endometrial and cervical cancer
tissues
Activation of Stat3 usually leads to the expression of downstream
genes, Bcl-xL, survivin, and Mcl-1, that are important for cancer
cell survival and chemoresistance. Immunohistochemistry was
carried out to detect the expression of p-Stat3 (Ser727), Bcl-xL,
survivin, and Mcl-1 in both endometrial and cervical cancer tissues
A
Ect1/E6E7
C33A
HeLa
SiHa
HT-3
RL95-2
Hec-1B
Ishikawa
Stat3
p-Stat3 (Y705)
p-Stat3 (S727)
p-Stat1 (Y701)
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Figure 2 (A) Expression of Stat3, Stat1 and Stat5 phosphorylation in
human immortalised cervical cell line (Ect1/E6E7) and cervical and
endometrial cancer cell lines. A total of 100mg of total protein of cell
lysates from various cell lines were resolved on 8% SDS–PAGE and
subjected to Western blot analysis using antibodies that recognise
phospho-specific Stat3 (Tyr705), Stat3 (Ser727), Stat1 (Tyr701), Stat5
(Tyr694), and GAPDH, respectively. (B) Densitometric quantitation of
phospho-Stat3 (Tyr705) and Stat3 (Ser727) expressions. The phospho-
Stat3 expressions are normalised to GAPDH expression in each cell line
and shown in percentage of phospho-Stat3 (Tyr705) in SiHa cells and
phospho-Stat3 (Ser727) in RL95-2 cells, respectively.
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carcinomas, the expressions of these genes are associated with
elevated p-Stat3 (Tyr705) with statistic significance (Po0.05). This
implied that activation of Stat3 promotes the expression of
antiapoptotic genes in these two types of cancers.
rAd-mediated transduction of dnStat3 in cervical cell lines
Since Stat3 activation may play a role in promoting cell growth and
survival in cervical and endometrial cancer cells, we subsequently
investigated whether the interference of Stat3 activation by
transduction of rAd/dnStat3 would affect cell growth or survival
of cervical cancer cells in vitro. We introduced dnStat3 into
HeLa and SiHa cervical cancer cell lines using an adenoviral vector
delivery system. HeLa and SiHa cells were infected with
rAd/dnStat3 (MOI¼10, 100, and 400). FLAG-tagged dnStat3
expression levels in cervical cancer cells were detected in
Western blots probed with an anti-FLAG antibody. Two days
post-infection, dnStat3 was expressed in HeLa and SiHa cells in a
dose-dependent manner, but not in untransduced cells and cells
transduced with rAd/eGFP (MOI¼400) (Figure 3A). The trans-
duction efficiency of rAd vector on these cells was determined by
infection of rAd/eGFP. More than 90% of cancer cells showed
green fluorescence by day 2 post-infection with rAd/eGFP at a MOI
of 400 (data not shown).
Differential dnStat3-mediated suppression on cell growth
of cervical cancer cells with elevated expression of p-Stat3
(Tyr705)
Cell growth of cervical cancer cells with elevated p-Stat3 (Tyr705)
was differentially suppressed in the presence of dnStat3. Cervical
cancer cells were transduced with either rAd/eGFP or rAd/dnStat3
(MOI¼10–400) (Figure 3B). Growth of cells with/without
transduction was normalised to untransduced controls at
day 2 post-transduction (Figure 3C). The growth rates of
untransduced cells were set at 100%. There were no adverse
effects by rAd/eGFP on cell growth as observed in HeLa and
SiHa cervical cancer cells when MOI of 400 were used. Cells
transduced with rAd/eGFP (MOI¼10 or 100) also showed no
adverse effect in cell growth (data not shown). When transduced
with rAd/dnStat3 (MOI¼400), HeLa and SiHa cells showed
dramatic decrease in cell growth with less than 5% and 20% of
untransduced control HeLa (Figure 3A) and SiHa (Figure 3B) cells,
respectively.
To investigate the selectivity of dnStat3-mediated cell growth
inhibition, HeLa, SiHa and a non-p-Stat3 (Tyr705) expressing cell
line, Ishikawa, were transduced with rAd/GFP and rAd/dnStat3
(MOI¼250). Although all three endometrial cancer cell lines
express non-detectable or very low levels of Stat3 phosphorylation
(Tyr705), we tested Ishikawa rather than RL95-2 and Hec-1B cell
line because Ishikawa cell line expresses lowest levels of Stat3
phosphorylation at Ser residue 727. MTT assay indicated that cell
viability of Ishikawa cells is not affected by dnStat3 expression
whereas HeLa (Figure 3D) and SiHa cell (data not shown) viability
was decreased.
Apoptosis induced by dnStat3 and a JAK/Stat3 small
molecular inhibitor through caspase-3 pathway
Loss of cell numbers in cells transduced with rAd/dnStat3
suggested cell death as the cause. We explored whether apoptosis
may contribute to the cell death. To investigate the mechanism
underlying the cervical cancer cell death, HeLa and SiHa cells were
fixed at day 2 post-transduction of rAd/eGFP or rAd/dnStat3 and
then subjected to immunofluorescent staining using an antibody
that recognises cleaved caspase 3 or Western blot analysis using
antibody that recognises cleaved PARP for apoptosis detection.
As expected, rAd/dnStat3 inhibited Stat3 pathway and induced
cleavage of caspase 3 in both cell lines (Figure 4A and B). There
were basal levels of cleaved caspase-3 in negative controls
(untransduced, transduced with rAd/eGFP, or DMSO sham) in
HeLa and SiHa cancer cells lines. However, apoptosis induced by
the expression of dnStat3 was evidenced as caspase 3 and PARP
were observed in dnStat3-expressing HeLa and SiHa cervical
cancer cell lines (Figure 4A–C). Furthermore, a small molecule
Table 1 The association of p-Stat3 (Tyr705) with the expression of p-Stat3 (Ser727) and potential Stat3 downstream targets in endometrial carcinomas
IHC – staining positive Association with P-Stat3 (Tyr705)
a
Total number of
cancer tissues Numbers (%) Numbers
a (%)
Pearson
v
2 test
b
P-Stat3 (Tyr705) 60 14 (23.3) 14 (100)
P-Stat3 (Ser727) 60 11 (18.3) 7 (63.6) Po0.05
Bcl-xL 60 21 (35.0) 13 (61.9) Po0.05
Survivin 60 14 (23.3) 10 (71.4) Po0.05
Mcl-1 60 21 (35.0) 12 (57.1) P40.05
aThe numbers associated with P-Stat3 (Tyr705) divided by total numbers of IHC-staining positive.
bPo0.05 is considered as statistically significant.
Table 2 The association of p-Stat3 (Tyr705) with the expression of p-Stat3 (Ser727) and potential Stat3 downstream targets in cervical carcinomas
IHC – staining positive Association with P-Stat3 (Tyr705)
a
Total numbers of
cancer tissues Numbers (%) Numbers
a (%)
Pearson
v
2 test
b
P-Stat3 (Tyr705) 104 25 (24.0) 25 (100)
P-Stat3 (Ser727) 104 24 (23.0) 18 (75.0) Po0.05
Bcl-xL 104 27 (25.9) 20 (74.0) Po0.05
Survivin 55 10 (18.2) 6 (60.0) Po0.05
Mcl-1 55 16 (29.0) 10 (62.5) Po0.05
aThe numbers associated with p-Stat3 (Tyr705) divided by total numbers of IHC-staining positive.
bPo0.05 is considered as statistically significant.
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sinhibitor that targets JAK/Stat3, JSI-124, also more selectively
induced cleavage of caspase 3 in HeLa and SiHa cancer cell lines
than Ishikawa cell line, which has low expression of elevated levels
of Stat3 phosphorylation (Tyr705) (Figure 4E).
DISCUSSION
Endometrial cancer is the most common gynecologic malignancy
in developed countries, with approximately 40000 new diagnoses
each year in the United States alone. There are about 10370 new
cases of invasive cervical cancer in the United States and about
3710 women will die from this disease. Constitutive Stat3 signaling
appears to play a role in the cell transformation and tumour
progression by stimulating cell growth, promoting tumour
angiogenesis, mediating immune evasion and conferring resistance
to apoptosis induced by chemotherapeutic agents (Niu et al, 2002;
Real et al, 2002; Wei et al, 2003; Wang et al, 2004). However,
whether Stat3 is activated in endometrial and cervical cancers is
not known. The present study investigated the activation Stat3 in
endometrial and cervical carcinomas, which should help us to
better understand the cancer progression of endometrial and
cervical cancers that involve the activation of multiple oncogenic
pathways including the constitutive Stat3 pathway. The elevated
levels of Stat3 phosphorylation were detected in 25.2% of 107 total
cervical cancer specimens (Supplementary Table 2) as well as three
out of four human cervical cancer cell lines. Although none of the
three endometrial cancer cell lines we studied expressed elevated
Stat3 phosphorylation, 20.8% of 115 total endometrial cancer
specimens showed elevated levels of Stat3 phosphorylation
(Supplementary Table 1). Our previous results also indicated that
Stat3 is activated in ovarian cancer (Huang et al, 2000). Therefore,
constitutive activation of Stat3 seems to be one of the common
molecular mechanisms to promote oncogenesis in gynecologic
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Figure 3 Transduction of dnStat3 inhibits cell growth and viability in cervical cancer cell lines. (A) Expression of dnStat3 mediated by rAd vector in a
dose-dependent manner in HeLa and SiHa cervical cancer cell lines. One hundred micrograms of cell lysates were analysed on 10% PAGE analysis and then
subjected to immunoblots probed with anti-FLAG, -Stat3 and – GAPDH antibodies. The dose-dependent expression of FLAG-tagged dnStat3 is according
to the increased expression levels of total Stat3 protein. There was no detectable FLAG-tagged dnStat3 in cell lysates of untransduced or cells transduced
with rAd/eGFP. (B) and (C) dnStat3 inhibits HeLa and SiHa cell growth. HeLa and SiHa cells were transduced with either rAd/dnStat3 or rAd/eGFP
(MOI¼10–400). Representative phase-contrast images of HeLa and SiHa cells 48h post-transduction were shown at magnification  100. Only
representative data (MOI¼400) are shown for cells transduced with rAd/eGFP for cells transduced with MOI lower than 400 showed no adverse effects on
cell growth. Cells in five random individual microscopic fields ( 100) were scored on day 2 post-transduction of rAd/eGFP or rAd/dnStat3. The cell growth
is shown in cell density/control (%). The averages and standard deviations are based on triplicate independent experiments. (D) dnStat3 reduces cell viability
of cancer cells with elevated phospho-Stat3 at 48h post-transduction. HeLa and Ishikawa cells were transduced with rAd/eGFP and rAd/dnStat3
(MOI¼250). Cell viability was analysed using MTT assay.
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scancers including ovarian, endometrial, and cervical cancers. We
observed that Stat3 is activated in cervical cancer early stages such
as Stage 1, suggesting that Stat3 is a target of chemoprevention
in cervical cancer. Inhibition of activated Stat3 in early stage(s)
of cervical cancer might prevent further progression of cervical
cancer. How Stat3 is activated in endometrial cancer is currently
unknown and it will be of interest to further examine the
mechanisms. Stat3 activation in cervical cancer is also largely
unclear but one of the mechanisms may be involved in interleukin-
6 (Wei et al, 2003). Immunohistochemistry on tissue arrays and
Western blots of cell lines showed that Stat3 activation through
phosphorylation at Ser 727 might be important for endometrial
and cervical malignancies. Stat1 and Stat5 might not be crucial for
these cancers since phosphorylation of these two STAT members
are not evident.
Since Stat3 phosphorylation at Tyr705 is elevated in cervical
and endometrial cancer tissues and Stat3 pathway has been shown
to participate in oncogenesis (Bromberg et al, 1999; Bowman
et al, 2000), we examined whether the inhibition of Stat3 pathway
by dnStat3 in cervical cancer cells could suppress cancer cell
growth. Suppression of cell growth was observed in cervical cancer
cells expressing dnStat3, whereas growth of untransduced cells
or transduced with rAd/GFP remained unaffected. This indicates
that the growth inhibition of cervical cancer cells is a dnStat3-
dependent inhibitory effect. Transduction of dnStat3 also induces
apoptosis in cervical cancer cells in vitro. Apoptosis caused
by dnStat3 is apparently through the caspase 3-dependent
pathway, since cleaved caspase 3 was detected in cancer cells
expressing dnStat3 or treated with JSI-124 as demonstrated by
immunofluorescent staining. Increased expressions of antiapopto-
tic Bcl-xL, survivin and Mcl-1 are strongly associated with the
elevated p-Stat3 (Tyr705) in cervical and endometrial cancer
tissues. They are the candidate targets by dnStat3 for its cell growth
inhibition and apoptosis induction. Our data strongly support
the possibility that the activated Stat3 pathway could serve as a
therapeutic target in cervical and possibly in endometrial cancers
using a dominant-negative Stat3 mutant or small molecular
inhibitors.
Other methods that targets the Stat3 signaling pathway in cancer
cells have also been explored, which include using anti-sense RNA
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Figure 4 Transduction of dnStat3 induces apoptosis through caspase 3 pathway in (A) HeLa and (B) SiHa cervical cancer cell lines day 2 post-
transduction. Cells were transduced with rAd/dnStat3 or rAd/eGFP (MOI¼400). Cells incubated with JSI-124 (5 and 10mM), a Stat3 inhibitor, and DMSO
served as a positive and negative control, respectively. Cells were fixed in methanol/acetone (v:v¼1:1) and then immunostained with anti-cleaved caspase-
3 antibody after 48h. Cleaved caspase-3 immunoreactivies were observed in cells transduced with rAd/dnStat3, but much less in cells transduced with rAd/
eGFP or the untransduced controls. Magnifications of all images were  100. The percentages of cleaved caspase-3 positive cells were scored in five
microscopic fields. The averages and standard deviations are based on three independent experiments. (C) dnStat3 induces cleavage of PARP in HeLa and
SiHa cell lines. HeLa and SiHa cells were transduced with rAd/dnStat3 and rAd/eGFP (MOI:10, 100 and 400). After 48h, cell lysates (100mg) were
fractionated using SDS–PAGE and subject to Western blots probed with anti-cleaved PARP and -GAPDH antibodies. Cleaved caspase 3: anticleaved-
caspase-3 antibody immunofluorescent staining; DAPI: nuclear staining with DAPI; none: untransduced cells.
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s(Grandis et al, 2000; Epling-Burnette et al, 2001; Calvin et al, 2003;
Chiarle et al, 2005), siRNA (Konnikova et al, 2003; Lee et al, 2004),
small molecules (Song et al, 2005; Turkson et al, 2005) and
decoy-oligos (Leong et al, 2003; Chan et al, 2004).
In summary, our results demonstrated for the first time that
Stat3 phosphorylation is elevated in clinical human endometrial
and cervical cancer samples. Stat3 appears to be one of the
oncogenic pathways activated in human endometrial and cervical
cancers. The constitutive Stat3 signaling may be a novel
therapeutic target for cancer intervention in cervical and
endometrial carcinomas.
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